Biomedtracker and Datamonitor Healthcare analysts have selected over 60 candidates with potential to launch in 2027. Two-thirds introduce mechanisms with no current market presence, and nearly half could shift standard of care.
For much of this cohort, regulatory pathways look largely de-risked. Market share will depend on payer access, formulary placement and launch sequencing.
This abridged report profiles five assets from our full analysis, spanning metabolic disease, oncology, renal and autoimmune indications. Several are at or near regulatory decision, with commercial infrastructure already taking shape.
The report covers:
- Five drugs with the scale and science to reshape their markets
- How each mechanism differs from what is already available
- Likelihood of approval and the regulatory milestones to watch
- Consensus sales forecasts and blockbuster potential
- Competitive context for each launch
Already a Biomedtracker or Datamonitor Healthcare subscriber? Log in to read the full report on the platform.
